Tadalafil Tablet
Product Images NDC 71610-728

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-728). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 20 mg (71610 0728 04)

Tadalafil USP 20 mg oral tablet label from Aphena Pharma Solutions - Tennessee, LLC. The label indicates a package of 4 tablets with storage instructions, NDC number 71610-0728-04, and packaging location in Cookeville, TN. It includes handling and safety warnings, batch number, and expiration date areas.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares Tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles), showing a greater decrease in IPSS score with Tadalafil across all weeks. Statistical significance (p<0.01) is noted at 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

Four line graphs depicting the effects of tadalafil on blood pressure over time (hours) compared to placebo. The graphs show changes in standing systolic and diastolic blood pressure and supine systolic and diastolic blood pressure, each plotted with time on the x-axis and difference in mmHg on the y-axis.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing changes in systolic blood pressure (mmHg) over 24 hours post-dose for Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg. The top graph depicts standing systolic blood pressure and the bottom graph depicts supine systolic blood pressure, with time post-dose on the x-axis and blood pressure change on the y-axis.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph displaying systolic blood pressure (mmHg) over time (hours) following administration of tadalafil or placebo, combined with doxazosin. Four lines represent different treatment groups: 20 mg tadalafil with doxazosin, placebo with doxazosin at low and high doses. The graph shows variations in blood pressure changes within a 12-hour period post-dose.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours). It compares three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The y-axis shows tadalafil concentration, and the x-axis shows time in hours, with data points and error bars.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The x-axis represents treatment duration in weeks, and the y-axis shows the change in IPSS score. Tadalafil 5 mg demonstrates a greater reduction in score compared to placebo, with a statistical significance of p<0.01.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment duration comparing Tadalafil 5 mg and placebo. The graph shows two lines: a solid line for Tadalafil with a more pronounced decrease, and a dashed line for placebo with a moderate decrease, highlighting statistically significant differences at certain points.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph titled 'Weeks of Therapy' showing least-squares mean change from baseline over 26 weeks. It compares two groups: Tadalafil/Finasteride and Placebo/Finasteride, with data points at weeks 0, 4, 12, and 26. The graph includes statistical annotations for significance levels (p<0.001, p<0.05).*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, the active ingredient. The image shows the molecular arrangement with labeled atoms and bonds consistent with the tadalafil molecule used in pharmaceutical formulations.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.